Skip to main content
Have a personal or library account? Click to login
Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat Cover

Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat

Acta Pharmaceutica
Volume 64 (2014): Issue 3 (September 2014)
By: ,  ,   and    
Open Access
|Oct 2014
References

References

  1. 1. J. K. Liao and U. Laufs, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118; DOI: 10.1146/annurev.pharmtox.45.120403.095748.
    Open DOISearch in Google Scholar
  2. 2. S. Wolfrum, K. S. Jensen and J. K. Liao, Endothelium-dependent effects of statins, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736; DOI: 10.1161/01.ATV.0000063385.12476.A7.
    Open DOISearch in Google Scholar
  3. 3. L. Taraseviciene-Stewart, R. Scerbavicius, K. H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper and N. F. Voelkel, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension, Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006) L668-L676; DOI: 10.1152/ ajplung.00491.2005.
    Search in Google Scholar
  4. 4. R. E. Girgis, D. Li, X. Zhan, J. G. Garcia, R. M. Tuder, P. M. Hassoun and R. A. Johns, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin, Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H938-945; DOI: 10.1152/ajpheart.01097.2002.
    Open DOISearch in Google Scholar
  5. 5. F. Simko, Statins: a perspective for left ventricular hypertrophy treatment, Eur. J. Clin. Invest. 37 (2007) 681-691; DOI: 10.1111/j.1365-2362.2007.01837.x.
    Open DOISearch in Google Scholar
  6. 6. P. J. Delahoy, D. J. Magliano, K. Webb, M. Grobler and D. Liew, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis, Clin. Ther. 31 (2009) 236-244; DOI: 10.1016/j.clinthera.2009.02.017.
    Open DOISearch in Google Scholar
  7. 7. M. Satoh and A. Satoh, 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension, J. Pharm. Pharm. Sci. 11 (2009) 118s-130s.
    Search in Google Scholar
  8. 8. X. Sun and D. D. Ku, Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H801-H809; DOI: 10.1152/ajpheart.01112.2007.
    Open DOISearch in Google Scholar
  9. 9. Y. Pei, P. Ma, X. Wang, W. Zhang, X. Zhang, P. Zheng, L. Yan, Q. Xu and G. Dai, Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism, Eur. J. Pharmacol. 666 (2011) 165-172; DOI: 10.1016/j. ejphar.2011.05.035.
    Search in Google Scholar
  10. 10. V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario and K. C. Dellsperger, Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1128-1139; DOI: 10.1152/ajpheart.00048.2009.
    Open DOISearch in Google Scholar
  11. 11. T. Kuang, J. Wang, B. Pang, X. Huang, E. D. Burg, J. X. Yuan and C. Wang, Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats, Pulm. Pharmacol. Ther. 23 (2010) 456-464; DOI: 10.1016/j.pupt.2010.02.003.
    Open DOISearch in Google Scholar
  12. 12. L. Zhao, A. Sebkhi, O. Ali, B. Wojciak-Stothard, L. Mamanova, Q. Yang, J. Wharton and M. R. Wilkins, Simvastatin and sildenafil combine to attenuate pulmonary hypertension, Eur. Respir. J. 34 (2009) 948-957; DOI: 10.1183/09031936.00143508.
    Open DOISearch in Google Scholar
  13. 13. D. S. Lee, Y. K. Kim and Y. W. Jung, Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension, Korean Circ. J. 40 (2010) 659-664; DOI: 10.4070/ kcj.2010.40.12.659.
    Open DOISearch in Google Scholar
  14. 14. X. L. Li, R. J. Guan, Q. H. Xu and Z. Y. Wu, [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats], Zhonghua Xin Xue Guan Bing Za Zhi. 39 (2011) 247-253.
    Search in Google Scholar
  15. 15. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger and F. Grimminger, Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension, Circ. Res. 94 (2004) 1101-1108; DOI: 10.1161/01.RES.0000126050.41296.8E.
    Open DOISearch in Google Scholar
  16. 16. M. Jasińska-Stroschein, J. Owczarek, A. Łuczak, and D. Orszulak-Michalak, The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: A hemodynamic and biochemical study, Pharmacology 91 (2013) 178-184; DOI: 10.1159/000346921.
    Open DOISearch in Google Scholar
  17. 17. N. Galiè, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger and G. Simonneau, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur. Heart. J. 30 (2009) 2493-2537; DOI: 10.1093/eurheartj/ehp297.
    Open DOISearch in Google Scholar
  18. 18. M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin and J. S. Gibbs, Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group, Simvastatin as a treatment for pulmonary hypertension trial, Am. J. Respir. Crit. Care Med. 181 (2010) 1106-1113; DOI: 10.1164/rccm.2009111-699OC.
    Open DOISearch in Google Scholar
  19. 19. C. Transon, T. Leemann and P. Dayer, In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors, Eur. J. Clin Pharmacol. 50 (1996) 209-215.
    Open DOISearch in Google Scholar
  20. 20. W. J. Zeng, C. M. Xiong, L. Zhao, G. L. Shan, Z. H. Liu, F. Xue Q. Gu, X. H. Ni, Z. H. Zhao, X. S. Cheng, M. R. Wilkins and J. G. He, Atorvastatin in pulmonary arterial hypertension (APATH) study, Eur. Respir. J. 40 (2012) 67-74; DOI: 10.1183/09031936.00149011.
    Open DOISearch in Google Scholar
  21. 21. E. Abulhul, K. McDonald, R. Martos, D. Phelan, J. P. Spiers, M. Hennessy, J. Baugh, C. Watson, C. O’Loughlin and M. Ledwidge, Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide, Clin. Ther. 34 (2012) 91-100; DOI: 10.1016/j.clinthera.2011.11.002.
    Open DOISearch in Google Scholar
  22. 22. Y. Teshima, K. Yufu, H. Akioka, T. Iwao, F. Anan, M. Nakagawa, H. Yonemochi, N. Takahashi, M. Hara and T. Saikawa, Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction, J. Cardiol. 53 (2009) 58-64; DOI: 10.1016/j.jjcc.2008.08.008.
    Open DOISearch in Google Scholar
  23. 23. D. Chen, D. Zhou, J. Qian, F. Chen, L. Guan, L. Dong and J. Ge, Atorvastatin prevents dehydromonocrotaline- induced pulmonary hypertension in beagles, Exp Lung Res. 38 (2012) 333-343; DOI: 10.3109/01902148.2012.702852.
    Open DOISearch in Google Scholar
  24. 24. S. Yigitaslan and B. Sirmagul, Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension, Clin. Exp. Hypertens. 34 (2012) 222-229; DOI: 10.3109/10641963.2011.631652.
    Open DOISearch in Google Scholar
  25. 25. K. T. Mouchaers, I. Schalij, M. A. de Boer, P. E. Postmus, V. W. van Hinsbergh, G. P. van Nieuw Amerongen, A. Vonk Noordegraaf and W. J. van der Laarse, Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil, Eur. Respir. J. 36 (2010) 800-807; DOI: 10.1183/09031936.00130209.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/acph-2014-0029 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 345 - 353
Accepted on: May 15, 2014
Published on: Oct 8, 2014
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
rosuvastatin,
sildenafil,
combination therapy,
pulmonary hypertension,
hemodynamic parameters
Related subjects:
Pharmacy,
Pharmacy, other

© 2014 Magdalena Jasińska-Stroschein, Jacek Owczarek, Anna Wesołowska, Daria Orszulak-Michalak, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 64 (2014): Issue 3 (September 2014)
Previous article
Next article